NEW YORK (AP) — In a Sept. 5 story about a new drug from Keryx Biopharmaceuticals, The Associated Press misstated the timing of the company’s stock movement. The stock had been falling before the FDA drug approval announcement was made.

A corrected version of the story is below:

Recommended Stories

FDA approves breakthrough hepatitis C drug

Alexion drug gets breakthrough therapy status

FDA approves Lilly, Boehringer diabetes drug